Randomized, Double-Blind, Placebo-Controlled Study of Modified Erzhi Granules in the Treatment of Menopause-Related Vulvovaginal Atrophy

Table 5

Female sexual function index.

	groups	baseline	4 weeks	8 weeks	12 weeks	4 weeks after drug withdrawal	p1	p2	p3	p4
FSFI	treatment group	12.79±8.55	13.09±8.83	13.45±9.05	13.76±9.36	13.46±9.16	<0.001	<0.001	<0.001	<0.001
	placebo group	12.26±8.39	12.47±8.33	12.42±8.48	12.38±8.52	12.27±8.43	0.549	0.905	0.411	0.190
	p	0.738	0.628	0.352	0.236	0.325
desire	treatment group	2.39±0.76	2.77±1.90	2.40±0.76	2.43±0.78	2.42±0.79	0.527	0.317	0.059	0.102
	placebo group	2.40±0.98	1.11±1.35	2.42±0.97	2.43±0.99	2.42±0.98	0.317	0.564	1.000	0.564
	p	0.841	0.778	0.930	0.947	0.960
arousal	treatment group	1.65±1.66	1.62±1.65	1.60±1.64	1.61±1.64	1.58±1.63	0.527	0.705	1.000	0.317
	placebo group	1.48±1.55	1.53±1.56	1.53±1.56	1.54±1.57	1.52±1.55	0.705	0.705	0.293	1.000
	p	0.710	0.818	0.924	0.951	0.906
lubrication	treatment group	1.92±1.94	2.13±2.16	2.45±2.42	2.47±2.45	2.41±2.39	<0.001	<0.001	<0.001	<0.001
	placebo group	1.80±1.90	1.89±1.94	1.89±1.94	1.89±1.94	1.89±1.92	0.102	0.102	0.102	0.194
	p	0.844	0.587	0.246	0.226	0.260
orgasm	treatment group	1.81±1.82	1.78±1.83	1.79±1.82	1.77±1.80	1.76±1.80	0.157	0.180	0.705	1.000
	placebo group	1.58±1.62	1.63±1.63	1.63±1.64	1.63±1.63	1.62±1.64	0.564	0.655	0.739	1.000
	p	0.527	0.644	0.597	0.669	0.698
satisfaction	treatment group	2.79±0.89	2.92±0.87	2.93±0.88	3.02±0.94	2.89±0.86	0.028	0.044	0.006	0.144
	placebo group	3.01±1.01	3.05±0.96	3.01±1.03	2.98±1.01	2.94±1.03	0.380	0.739	0.448	0.234
	p	0.212	0.404	0.749	0.888	0.741
pain	treatment group	2.24±2.15	2.25±2.23	2.29±2.26	2.47±2.42	2.40±2.36	0.102	0.067	0.005	0.020
	placebo group	2.00±1.97	1.95±1.98	1.95±2.00	1.90±1.95	1.89±1.92	0.317	0.414	0.323	0.283
	p	0.431	0.349	0.297	0.225	0.255